Literature DB >> 18480227

Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207.

Nacer Lounis1, Tom Gevers, Joke Van Den Berg, Tom Verhaeghe, Rolf van Heeswijk, Koen Andries.   

Abstract

The levels of TMC207 (R207910) that can be reached in mouse organs and the sputa of treated patients easily exceed the MIC of the compound and can therefore interfere with in vitro bacterial titrations. We studied the usefulness of protein-enriched media for the prevention of such drug carryover effects. The average MIC of Mycobacterium tuberculosis was determined on three different media: unsupplemented 7H11 agar (MIC = 0.03 microg/ml), 7H11 agar supplemented with 5% bovine serum albumin (BSA; MIC = 1 microg/ml), and Lowenstein-Jensen medium (MIC = 14.33 microg/ml). In a second stage of the study, the maximal noninhibitory concentrations (MNICs) of TMC207 were determined by adding TMC207 to the bacterial inoculum rather than to the culture medium. These MNICs were 0.97 microg/ml for 7H11 agar, 32.33 microg/ml for 7H11 agar with 5% BSA, and 96.33 microg/ml for Lowenstein-Jensen medium. Both protein-enriched media were able to prevent drug carryover effects, but the use of 7H11 medium supplemented with 5% BSA is preferred for practical reasons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18480227      PMCID: PMC2446915          DOI: 10.1128/JCM.00177-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

2.  Use of an oral antiseptic bioadhesive tablet in dogs.

Authors:  P Gruet; C Gaillard; B Boisramé; D Duffaut; A M Grimoud; G Camy
Journal:  J Vet Dent       Date:  1995-09       Impact factor: 0.857

3.  Variables in demonstrating methicillin tolerance in Staphylococcus aureus strains.

Authors:  K Ishida; P A Guze; G M Kalmanson; K Albrandt; L B Guze
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

4.  Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Authors:  Nacer Lounis; Nicolas Veziris; Aurélie Chauffour; Chantal Truffot-Pernot; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

5.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Development and validation of a neutralizer system for in vitro evaluation of some antiseptics.

Authors:  W Sheikh
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

7.  Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.

Authors:  R Rustomjee; A H Diacon; J Allen; A Venter; C Reddy; R F Patientia; T C P Mthiyane; T De Marez; R van Heeswijk; R Kerstens; A Koul; K De Beule; P R Donald; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

8.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.

Authors:  C M Perronne; R Malinverni; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

  9 in total
  10 in total

1.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.

Authors:  A H Diacon; J S Maritz; A Venter; P D van Helden; K Andries; D F McNeeley; P R Donald
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-04       Impact factor: 3.267

Review 3.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

4.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 5.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

6.  Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.

Authors:  Koen Andries; Tom Gevers; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

7.  Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.

Authors:  Deepak V Almeida; Paul J Converse; Till F Omansen; Sandeep Tyagi; Rokeya Tasneen; Jeongjun Kim; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.

Authors:  Tae Sung Kim; Jin Ho Choe; Young Jae Kim; Chul-Su Yang; Hyun-Jin Kwon; Jinsun Jeong; Guehye Kim; Da Eun Park; Eun-Kyeong Jo; Young-Lag Cho; Jichan Jang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

9.  Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis.

Authors:  Jian Xu; Paul J Converse; Anna M Upton; Khisimuzi Mdluli; Nader Fotouhi; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

10.  Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.

Authors:  Ben Gold; Julia Roberts; Yan Ling; Landys Lopez Quezada; Jou Glasheen; Elaine Ballinger; Selin Somersan-Karakaya; Thulasi Warrier; J David Warren; Carl Nathan
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.